http://www.regentherapeutics.com/regen

Consider a company with a market cap of around 10 million which could well in the future be generating revenue well in excess of that figure every year. Interested then read on and DYOR on Regen Therapeutics.

For some time now I have been a shareholder of RGT who have been working with a patented product Colostrinin as a treatment for Alzheimers. Tests so far would seem to indicate that it is a success and they are currently refining a pharmaceutical product.

Meantime they are also pushing forward on the nutraceutical front as tests have shown positive results in respect of mild cognitive disorders (memory loss etc). Further research is being carried out regarding other major illnesses. As at mid 2007 a launch is scheduled in the US for Q4 and there are rumours of an earlier launch in Australia possibly imminent based on the fact that adverts are already starting to appear see:- http://www.quantumevolution.com.au/oscommerce/index.php

They have also acquired a contract research organisation which should mean that research money for clinical trials that had previously been spent will now be kept inside the group.

February 2006 has seen Regen acquire the rights, following a feasibility study, in respect of other uses for a well known drug (Zolpidem) that has undergone phase 2 clinical trials where results are expected around August 2007. The new use relates to the positive effects that have been seen when treating stroke victims with the drug. There has been a lot of press interest which a web search should reveal.

An interview with the chairman (Percy Lomax) in the summer of 2004 talked of a nutraceutical product producing royalty payments of 10% on a possible 100 million sales per annum. The pharmaceutical version which also requires a licensing partner will if successful have projected sales of 1-5 billion again which would generate royalty payments to Regen. I leave you to contemplate just how high the share price would be if this were the case but suffice to say it will be many many times what it is now.

Acquisition (Oct 2004) of Guildford Clinical Pharmacology unit demonstrates not only that they are progressive and expanding but also thinking strategically for GCPUL being a research based company no doubt Regen can now keep such costs within the group whereas before testing had to be paid for elsewhere. This acquisition also means that they have revenue and are therefore no longer a "virtual" company.

A share issue in July 2007 means that they should now have funds in hand to take them through to cash generation. Hopefully this means we have seen the last of the issues excepting any used by way of acquiring profitable companies.

The North America link is an interesting one as perhaps in readiness for the launch of Colostrinin out there Regen set up an ADR programme which became effective in March 2005. ADR's ( American Depositary Receipts) are a way for US investors to buy shares in UK companies. In Regen's case one ADR is equivalent to 200 Regen UK shares so when an ADR is purhased the Bank of New York will buy the proportionate number of UK shares and convert them into ADR's for the investor. At present this is not a factor however with the launch of Colostrinin out there if successful it may mean that US investors will want to be involved in the company and that will have a direct positive impact on our share price. In the US Colostrum (from which Colostrinin is produced )is already a recognised and popular health product and so demand should be good.

So all in all exciting times ahead. There can be few shares around that offer the potential of this one although as always DYOR and good luck with your investments whatever you decide here.

queen1

Do you know anything about David...if not may I suggest you do some homework on this individual, because if you do you will find out that he is very unpleasant .

On ADVFN he goes under the nickname of 10JimB and Jim_ Bentley Davis.

Good luck with RGT.

What A LOAD OF RUBBISH FORM A DISGRUNTLED UNFORTUNATE COH SHARE OWNER WHO SIMPLY COULD NOT TAKE THE EXPOSURE I GAVE HIS PET SHARE!

What a child he should be banned from all financial BBs.

Queen1 please take up the little boy's offer and do you homeworks on me, send me an email and if your are ever down in Plymstock drop by, especially if your any good at building.

BMW WHEN ARE YOU GOING TO GROW UP?

I read them all and only post here

now now you two..lets keep to the subject in hand..it seems to me that promotional exposure can only help the s.p. looking at company products and development so far.

watcher

Thanks all - I have my own "idiot" who seems to follow me around at the moment (the latest chapter in the saga is currently running on the CEN thread) so I'm happy to keep out of another one. It would be good though David if your posts could be balanced otherwise their worth may be diminished.

Good luck to all holders anyway!

queen1

Don't say I did'nt warn you.

Good luck.

Queen1, I try to balance the SP performance with time.

Conclusion RGT is not going anywhere fast.

nice to watch that strong buying pattern today..patients is a key..he he

watcher

Down I see despite all the rampings.

Be careful with this one its a money burner!

won't be down here for long if this pattern of buys continues

Even with that volume it will be difficult to shift the SP just watch.

Oh shut up David - take it somewhere else. You really are a bore.

queen1
His not far wrong there's an over-hang here the sp is hard to shift.

He may not be driver but there's something called balance: I don't like ramping and I don't like de-ramping, both in equal measure. And if you follow Mr D's posting throughout the BB's you'll see he's a de-ramper through & through.

Hi all. Not sure if you've been keeping in touch with events elsewhere but research has revealed that Colostrinin is being advertised for sale in Australia. It is now the 4th best seller on one of the sites:- http://www.quantumevolution.com.au/oscommerce/index.php

At this point there has been no official announcement from Regen about a launch. A poster elsewhere has been told that whilst Australia will now be the first launch the official date has not been reached and hence they cannot make an announcement. I, like a numberof others have placed an order and received an email to confirm it's being shipped so will be interested to see when I receive it. Certainly strikes as good news that not only is a license being sorted for another part of the world but it is actually launching sooner than the US and thus revenue is that much closer.

Meantime Zolpidem had a one page feature in the Mail yesterday and I gather was discussed on a breakfast programme today so press interest is building in advance of the trial results data being published in a few weeks time.

Elsewhere the vet trials were due to start at the beginning of June so I assume they are under way.

Following the recent issue there must still be an overhang of at least 20-30 million shares and yet Hoodless seem to be very quiet. Initially they seemed to be pushing them actively but then nothing and they are not the ones on the offer in the market. The first hurdle when some of this news does break will be to clear any overhang but things are certainly looking interesting for the near future.

In relation to the heading of this thread there is only one way RGT will rocket and that is to center of the planet.

However good luck to all you optermists who are brave enough to hold.

I bought last year at under 1p and then sold at just under 2p thats the best rake off for a few years for tis one,

When the over-hang is out of the way this will move, on my watch list.

Thanks Gantenbrink for an informative and balanced post. Potentially interesting times ahead.

Far from it Queen1 this share is not going anywhere, and if it does start to move there will be the inevitable cash call.

do us all a favour david

watcher

I f I can I most certainly will, but if in volves a restriction on my right to my opinion, then obviously I would have to refuse as there is so muchrubbish talked about this share it coulod mislead others into thinking its going places and clearl its not.

Expansion would call for further dilution.

This company need a better quality management. I know I held it for about a year. Watched it rise on a bag full of empty promises that came to nothing and then dive back.

That said I sold at the top and I did make a few bob out of it and will buy back again if I see a chance of the SP riing maybe in 2009-